Does the media favor VNDA or VRCA?

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 4 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.85 beat Verrica Pharmaceuticals' score of 0.41 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VRCA or NMRA?

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.25 beat Verrica Pharmaceuticals' score of 0.41 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRN or VRCA?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 6 mentions for Amarin. Amarin's average media sentiment score of 0.52 beat Verrica Pharmaceuticals' score of 0.41 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VRCA or TTRX?

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Turn Therapeutics. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.83 beat Verrica Pharmaceuticals' score of 0.41 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor VRCA or ZNTL?

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.76 beat Verrica Pharmaceuticals' score of 0.41 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Verrica Pharmaceuticals (VRCA) Competitors

$5.69 +0.62 (+12.23%)

As of 08/28/2026 04:00 PM Eastern

Compare

VRCA vs. VNDA, NMRA, AMRN, TTRX, and ZNTL

Should you buy Verrica Pharmaceuticals stock or one of its competitors? Verrica Pharmaceuticals's main competitors and comparable companies include Vanda Pharmaceuticals (VNDA), Neumora Therapeutics (NMRA), Amarin (AMRN), Turn Therapeutics (TTRX), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by company insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vanda Pharmaceuticals has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 4 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.85 beat Verrica Pharmaceuticals' score of 0.41 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vanda Pharmaceuticals presently has a consensus target price of $13.70, indicating a potential upside of 158.98%. Verrica Pharmaceuticals has a consensus target price of $12.67, indicating a potential upside of 122.61%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Verrica Pharmaceuticals has lower revenue, but higher earnings than Vanda Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A

Verrica Pharmaceuticals has a net margin of -102.84% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Summary

Vanda Pharmaceuticals beats Verrica Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Neumora Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Neumora Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Neumora Therapeutics' return on equity of -242.28% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Neumora Therapeutics	N/A	-242.28%	-131.32%

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the broader market.

Verrica Pharmaceuticals has higher revenue and earnings than Neumora Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

Verrica Pharmaceuticals currently has a consensus price target of $12.67, suggesting a potential upside of 122.61%. Neumora Therapeutics has a consensus price target of $6.57, suggesting a potential upside of 372.76%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 26.9% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 4 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.25 beat Verrica Pharmaceuticals' score of 0.41 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neumora Therapeutics beats Verrica Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Amarin?

Amarin (NASDAQ:AMRN) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 6 mentions for Amarin. Amarin's average media sentiment score of 0.52 beat Verrica Pharmaceuticals' score of 0.41 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verrica Pharmaceuticals has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A

Amarin has a net margin of -14.56% compared to Verrica Pharmaceuticals' net margin of -102.84%. Amarin's return on equity of -0.20% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-14.56%	-0.20%	-0.14%
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%

Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amarin currently has a consensus target price of $13.00, indicating a potential downside of 6.94%. Verrica Pharmaceuticals has a consensus target price of $12.67, indicating a potential upside of 122.61%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Verrica Pharmaceuticals beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Turn Therapeutics?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Turn Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Turn Therapeutics' return on equity of -230.84% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Turn Therapeutics	N/A	-230.84%	-53.19%

Verrica Pharmaceuticals presently has a consensus target price of $12.67, indicating a potential upside of 122.61%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential downside of 18.70%. Given Verrica Pharmaceuticals' higher possible upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Turn Therapeutics. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.83 beat Verrica Pharmaceuticals' score of 0.41 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Turn Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

Turn Therapeutics beats Verrica Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 5 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.76 beat Verrica Pharmaceuticals' score of 0.41 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Verrica Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$30.32M	3.22	-$17.89M	-$1.67	N/A
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A

Verrica Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Zentalis Pharmaceuticals' return on equity of -70.18% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Verrica Pharmaceuticals presently has a consensus target price of $12.67, suggesting a potential upside of 122.61%. Zentalis Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 77.63%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Verrica Pharmaceuticals beats Zentalis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$97.75M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-3.41	787.65	273.16	25.45
Price / Sales	3.22	793.09	604.43	75.83
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	22.76	11.97	12.98	6.14
Net Income	-$17.89M	$2.83B	$3.48B	$348.86M
7 Day Performance	18.05%	0.39%	0.13%	-0.80%
1 Month Performance	8.17%	5.34%	7.08%	4.13%
1 Year Performance	1.79%	6.05%	24.67%	15.17%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	4.1864 of 5 stars	$5.69 +12.2%	$12.67 +122.6%	+1.8%	$97.75M	$30.32M	N/A	40	News Coverage Analyst Forecast High Trading Volume
VNDA Vanda Pharmaceuticals	2.4666 of 5 stars	$5.33 +0.9%	$13.70 +157.0%	+11.8%	$319.24M	$216.10M	N/A	290
NMRA Neumora Therapeutics	2.9078 of 5 stars	$1.53 -6.4%	$6.57 +330.9%	-19.7%	$306.27M	N/A	N/A	108	Gap Down
AMRN Amarin	0.8974 of 5 stars	$13.84 -1.8%	$13.00 -6.1%	-7.1%	$297.62M	$213.65M	N/A	360	News Coverage High Trading Volume
TTRX Turn Therapeutics	1.8923 of 5 stars	$9.68 +2.3%	$8.00 -17.4%	N/A	$281.80M	N/A	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. VNDA, NMRA, AMRN, TTRX, and ZNTL

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Summary

How does Verrica Pharmaceuticals compare to Neumora Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Summary

How does Verrica Pharmaceuticals compare to Turn Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. VNDA, NMRA, AMRN, TTRX, and ZNTL

How does Verrica Pharmaceuticals compare to Vanda Pharmaceuticals?

Do institutionals and insiders have more ownership in VNDA or VRCA?

Which has more volatility & risk, VNDA or VRCA?

Does the media favor VNDA or VRCA?

Do analysts prefer VNDA or VRCA?

Which has stronger valuation & earnings, VNDA or VRCA?

Is VNDA or VRCA more profitable?

Summary

How does Verrica Pharmaceuticals compare to Neumora Therapeutics?

Is VRCA or NMRA more profitable?

Which has more volatility and risk, VRCA or NMRA?

Which has stronger valuation and earnings, VRCA or NMRA?

Do analysts prefer VRCA or NMRA?

Do insiders and institutionals believe in VRCA or NMRA?

Does the media refer more to VRCA or NMRA?

Summary

How does Verrica Pharmaceuticals compare to Amarin?

Does the media prefer AMRN or VRCA?

Which has better earnings & valuation, AMRN or VRCA?

Is AMRN or VRCA more profitable?

Which has more volatility & risk, AMRN or VRCA?

Do institutionals & insiders believe in AMRN or VRCA?

Do analysts recommend AMRN or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Turn Therapeutics?

Do institutionals and insiders believe in VRCA or TTRX?

Is VRCA or TTRX more profitable?

Do analysts recommend VRCA or TTRX?

Does the media prefer VRCA or TTRX?

Which has higher earnings & valuation, VRCA or TTRX?

Summary

How does Verrica Pharmaceuticals compare to Zentalis Pharmaceuticals?

Does the media favor VRCA or ZNTL?

Which has better earnings & valuation, VRCA or ZNTL?

Which has more volatility & risk, VRCA or ZNTL?

Do insiders & institutionals believe in VRCA or ZNTL?

Is VRCA or ZNTL more profitable?

Do analysts prefer VRCA or ZNTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools